

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	RELEASE BY SECURED PARTY
CONVEYING PARTY DATA	
Name	Execution Date
MidCap Financial, LLC	02/08/2013
RECEIVING PARTY DATA	
Name:	CeNeRx BioPharma, Inc.
Street Address:	270 Cornerstone Drive Suite 103
City:	Cary
State/Country:	NORTH CAROLINA
Postal Code:	27519
PROPERTY NUMBERS Total: 8	
Property Type	Number
Patent Number:	7632836
Patent Number:	7812050
Application Number:	13143408
Application Number:	13143403
Application Number:	12330434
PCT Number:	US2007024547
PCT Number:	US2007015533
Patent Number:	8313766
CORRESPONDENCE DATA	
Fax Number:	
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Phone:	919-781-4000
Email:	lblackwell@wyrick.com
Correspondent Name:	Linda Blackwell
Address Line 1:	4101 Lake Boone Trail Suite 300
Address Line 2:	Wyrick Robbins Yates & Ponton LLP

OP \$320.00 7632836

Address Line 4: Raleigh, NORTH CAROLINA 27607

ATTORNEY DOCKET NUMBER: 20515.1 LFB

NAME OF SUBMITTER: Robert Goodridge, General Counsel

This document serves as an Oath/Declaration (37 CFR 1.63).

Total Attachments: 6

source=Midcap Financial LLC Release#page1.tif
source=Midcap Financial LLC Release#page2.tif
source=Midcap Financial LLC Release#page3.tif
source=Midcap Financial LLC Release#page4.tif
source=Midcap Financial LLC Release#page5.tif
source=Midcap Financial LLC Release#page6.tif

RELEASE OF INTELLECTUAL PROPERTY SECURITY INTEREST

THIS RELEASE OF INTELLECTUAL PROPERTY SECURITY INTEREST made and entered effective as of February 8, 2013, by the below signatory hereto (the "Lender"), in favor of CeNeRx BioPharma, Inc., a Delaware corporation, (the "Borrower").

WHEREAS, Lender and Borrower were parties to a certain Amended and Restated Intellectual Property Security Agreement dated as of June 11, 2009 (the "Security Agreement") and recorded in the United States Patent and Trademark Office on October 20, 2009 at Reel 4081/ Frame 0448 and at Reel 023397/Frame 0175, and on November 12, 2009 at Reel 4095/Frame 0310 and at Reel 023509/Frame 0882, under which Borrower granted Lender a security interest in Borrower's trademarks and patents, including but not limited to the trademarks and patents listed on Schedule A hereto; and

WHEREAS, Lender now desires to release and terminate any security interest it may have as to the trademarks and patents listed on Schedule A (the "Security Interest").

NOW THEREFORE, for good and valuable consideration, receipt and sufficiency of which are hereby acknowledged, Lender hereby terminates the Security Interest and releases to Borrower all interest which Lenders possess or are otherwise entitled to in the patents and trademarks listed on Schedule A hereto by virtue of such Security Agreement.

[Signature page follows.]

IN WITNESS WHEREOF, the undersigned have executed this Release of Intellectual Property Security Interest as of the date first above written.

LENDER:

MIDCAP FINANCIAL, LLC

By: 

Name: Robert Goodridge

Title: General Counsel

SCHEDULE A

Copyrights

<u>Description</u>	<u>Registration/ Application Number</u>	<u>Registration/ Application Date</u>
NONE	N/A	N/A

PATENTS

<u>Title</u>	<u>Patent/Patent Application Number (Publication Number)</u>	<u>Issue/Filing Date</u>
Methods of treating Rett Syndrome	12/117,586 20080280983	05/08/2008
Dialkylamino Alkyl Esters of Pivagabine as Medicaments for the Treatment of Central Nervous System Disorders	US 7,632,836 20090111813	12/15/2009
Polymorphic Form Of Fluoro-7-(2,2,2-Trifluoroethoxy) Phenoxathiin-10,10-Dioxide	US 7,812,050 11/773,892 20080009542	10/12/2010 07/05/2007 01/10/2008
Oral Enteric Antidepressant Formulation	13/143,408 20120003303	01/08/2010 01/05/2012
Oral Sustained Release Antidepressant Formulation	13/143,403 20120003274	01/08/2010 01/05/2012
Pharmaceutical Compounds	12/330,434 20090081123	12/08/2008
Methods of treating Rett Syndrome	PCT/US2008/063129	11/20/2008
Dialkylamino Alkyl Esters of Pivagabine as Medicaments for the Treatment of Central Nervous System Disorders	PCT/US2007/024547	06/05/2008
Polymorphic Form Of Fluoro-7-(2,2,2-Trifluoroethoxy) Phenoxathiin-10,10-Dioxide	PCT/US2007/015533	01/17/2008
Oral Antidepressant Formulation with Reduced Excipient Load	US 8,313,766 12/860,358 20110206769	11/20/2012 08/20/2010 08/25/2011

TRADEMARKS

<u>Description</u>	<u>Registration/Application Number</u>	<u>Registration/Application Date</u>
CENERX	3,662,094	07/28/2009
CENERX (Canada)	1,333,088	01/29/2007
MERIMA	77/467,853	05/07/2008
MYRIMA	77/467,852	05/07/2008
ATYRIMA	77/467,850	05/07/2008
TRIRIMA	3,687,175	09/22/2009
ATYREMA	77/478,437	05/19/2008
TYRIMA	77/094,042	01/29/2007
AYRENE	77/807,249	08/18/2009

SCHEDULE D

Mask Works

<u>Description</u>	<u>Registration/ Application Number</u>	<u>Registration/ Application Date</u>
NONE	N/A	N/A